Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) was the target of a significant growth in short interest in October. As of October 15th, there was short interest totalling 159,900 shares, a growth of 300.8% from the September 30th total of 39,900 shares. Currently, 1.0% of the company’s stock are sold short. Based on an average daily volume of 3,050,000 shares, the days-to-cover ratio is presently 0.1 days.
Bluejay Diagnostics Stock Up 4.0 %
Shares of BJDX traded up $0.00 during mid-day trading on Friday, hitting $0.10. 1,823,870 shares of the company’s stock were exchanged, compared to its average volume of 1,097,385. Bluejay Diagnostics has a twelve month low of $0.08 and a twelve month high of $34.24. The firm has a fifty day moving average of $0.16 and a two-hundred day moving average of $1.87. The stock has a market cap of $34,776.00, a price-to-earnings ratio of 0.00 and a beta of 0.70.
Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($5.12) EPS for the quarter.
Hedge Funds Weigh In On Bluejay Diagnostics
Bluejay Diagnostics Company Profile
Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
Featured Articles
- Five stocks we like better than Bluejay Diagnostics
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Texas Roadhouse Stock Steering for New Highs This Year
- Following Congress Stock Trades
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- The Most Important Warren Buffett Stock for Investors: His Own
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.